TQB6411 injection

DRUG2 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Advanced Malignant TumorsEsophageal Cancer

Phase 1

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

RecruitingNCT07043751

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Advanced Malignant Tumors

Start: 2025-07-15End: 2028-06-01Target: 216Updated: 2026-01-21

Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer

RecruitingNCT07367516

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Esophageal Cancer

Start: 2026-02-12End: 2027-03-01Target: 105Updated: 2026-09-15

Related Papers

First-in-human phase 1 study of TQB6411, an EGFR/c-Met bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Journal of Clinical Oncology2026-05-27